ClinicalTrials.gg
Status unknownNCT02902887Updated Apr 5, 2019

Monitored Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia

An interventional study of Controlled Intermittent Alternate Occlusion (CIAO ) glasses in Intermittent Exotropia, sponsored by Salus University. Status unknown at 1 site in United States. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2019-04-05.

Sponsored by Salus University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
3 Years to 11 Years
Sex
All
01

Study summary

This study presents an opportunity to understand a novel, previously unreported controlled intermittent alternate occlusion (CIAO) therapy glasses, which may improve the control of Intermittent exotropia (IXT).

02

Conditions studied

  • Intermittent Exotropia

Browse trials for

03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

Salus University is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following criteria must be met for the patient to be enrolled in the study:

  1. Age 3 to 11 years old
  2. Intermittent exotropia (manifest deviation) meeting all of the following criteria:

    • Intermittent exotropia at distance OR constant exotropia at distance and either intermittent exotropia or exophoria at near
    • Exodeviation at least 10PD at distance OR 15PD at near measured by prism and alternate cover test (PACT)
  3. No previous surgical or non-surgical treatment for IXT (other than refractive correction)
  4. Visual acuity in the worse eye 20/40 (0.3 logMAR) or better on ATS HOTV for ages 3 - 5 and 20/25 (0.1 logMAR) or better on ATS HOTV for ages 6 - 11
  5. No hyperopia greater than +3.50 D spherical equivalent in either eye
  6. No myopia greater than -6.00 D spherical equivalent in either eye
  7. Patients must be wearing refractive correction (spectacles or contact lenses) for at least one week if refractive error (based on cycloplegic refraction performed within 6 months) meets any of the following:

    • Myopia > -0.50 D spherical equivalent in either eye
    • Anisometropia > 1.00 D spherical equivalent
    • Astigmatism in either eye > 2.00 D if ≤ 5 years old and > 1.50 D if > 5 years old

    Refractive correction for patients meeting the above refractive error criteria must meet the following guidelines:

    • Anisometropia spherical equivalent must be within 0.25D of the full anisometropic difference correction
    • Astigmatism cylinder must be within 0.25D of full correction and axis must be within 5 degrees of full correction.
    • For hyperopia, the spherical component can be reduced at investigator discretion provided the reduction is symmetrical. Prescribing any refractive correction to yield lenses that are more myopic than -0.50 D spherical equivalent (SE) is considered deliberate overminus and is not allowed at enrollment. However, prescribing no correction or prescribing less than the full cycloplegic hyperopic correction (i.e., prescribing reduced plus) is not considered the same as overminusing for this protocol and is allowed because most patients without IXT but with hyperopic SE refractions in this range would not typically be prescribed a refractive correction.
    • For myopia, the intent is to fully correct, but the spherical component can be undercorrected by investigator discretion provided the reduction is symmetrical and results in no more than -0.50 D SE residual (i.e., uncorrected) myopia. Prescribing a correction that yields more than 0.50 D more minus SE than the cycloplegic refraction SE is considered deliberate overminus and is not allowed at enrollment.

    Note that the refractive correction guidelines and the requirement to wear refractive correction for at least one week apply not only to patients who require refractive correction under the above criteria but also to any other patient who is wearing refractive correction.

  8. No atropine use within the last week
  9. Gestational age > 34 weeks and birth weight > 1500 grams
  10. Patient and/or parent is willing to accept randomization to either observation or CIAO therapy.
  11. Parent has a phone (or access to phone) and is willing to be contacted

Exclusion criteria

Exclusion Criteria:

  1. Only phoria at both distance and near
  2. Prior non-surgical treatment for IXT other than refractive correction (e.g., vergence therapy, occlusion, vision therapy/orthoptics, or deliberate over-minus with spectacles more than 0.50D)
  3. Previous amblyopia treatment other than refractive correction within 1 year
  4. Vision therapy/orthoptics for any reason within the last year
  5. Interocular visual acuity difference more than 0.2 logMAR (2 lines on ATS HOTV for patients 3 to \< 7 years old or 10 letters on E-ETDRS for patients ≥ 7 years old)
  6. Investigator planning to initiate amblyopia treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Monitored CIAO therapy

    Participants wear 3-hour CIAO therapy

    Device: Controlled Intermittent Alternate Occlusion (CIAO ) glasses

  • No intervention
    Observation

    No intervention, just observation

Interventions

  • DeviceControlled Intermittent Alternate Occlusion (CIAO ) glasses

    Monitored CIAO therapy glasses

06

What researchers measure

Primary outcomes

  1. Control of the exodeviation assessment (scaled 1-5)

    Intermittent Exotropia Control Scale (1-5) 5 = Constant exotropia 4 = Exotropia \> 50% of the 30-second period before dissociation 3 = Exotropia \< 50% of the 30-second period before dissociation 2 = No exotropia unless dissociated, recovers in \> 5 seconds 1 = No exotropia unless dissociated, recovers in 1-5 seconds 0 = No exotropia unless dissociated, recovers in \< 1 second (phoria)

    Time frame: 3-month

07

Study locations

1 of 1 sites recruiting
  • Salus University
    Elkins Park, Pennsylvania, United States
    Recruiting
    • Jingyun Wang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2016 (actual). Primary completion is estimated for May 2021, 57 months after the start.

Of 29 interventional studies with no phase under Exotropia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2016
First posted
Sep 16, 2016
StartActual
Aug 2016
Primary completionEst.
May 2021
CompletionEst.
May 2021
Last update
Apr 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02902887
Lead sponsor
Salus University
Responsible party
Sponsor
First posted
Sep 16, 2016
Start date
Aug 2016
Primary completion
May 2021 (estimated)
Completion
May 2021 (estimated)
Last update
Apr 5, 2019

Study contacts

Jingyun Wang, PhD
Contact
jwang@salus.edu
215-780-1376

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion